Zelpultide Alfa
Bronchopulmonary Dysplasia (BPD) in preterm infants
Key Facts
About Airway Therapeutics
Airway Therapeutics is a private, clinical-stage biotech founded in 2011 and based in Cincinnati, Ohio. The company is advancing zelpultide alfa, a recombinant version of human surfactant protein D (SP-D), as a foundational immune-modulating therapy. With a Phase 2b/3 program in BPD for preterm neonates actively progressing and regulatory support from the EMA, the company is positioning its platform for broader applications in acute and chronic inflammatory lung diseases. Airway represents a focused investment in a novel biologic approach to unmet needs in respiratory medicine.
View full company profileAbout Airway Therapeutics
Airway Therapeutics is a private, clinical-stage biotech founded in 2011 and based in Cincinnati, Ohio. The company is advancing zelpultide alfa, a recombinant version of human surfactant protein D (SP-D), as a foundational immune-modulating therapy. With a Phase 2b/3 program in BPD for preterm neonates actively progressing and regulatory support from the EMA, the company is positioning its platform for broader applications in acute and chronic inflammatory lung diseases. Airway represents a focused investment in a novel biologic approach to unmet needs in respiratory medicine.
View full company profileAbout Airway Therapeutics
Airway Therapeutics is a private, clinical-stage biotech founded in 2011 and based in Cincinnati, Ohio. The company is advancing zelpultide alfa, a recombinant version of human surfactant protein D (SP-D), as a foundational immune-modulating therapy. With a Phase 2b/3 program in BPD for preterm neonates actively progressing and regulatory support from the EMA, the company is positioning its platform for broader applications in acute and chronic inflammatory lung diseases. Airway represents a focused investment in a novel biologic approach to unmet needs in respiratory medicine.
View full company profile